Sanofi Pasteur has taken yet another step forward in the development of its investigational, novel tetravalent Dengue vaccine candidate with advanced clinical studies among children and adults in Singapore and Vietnam. Part of a global clinical study programme being undertaken in endemic regions in Asia and Latin America, these studies mark the expansion of sanofi-aventis Group‘s Asia-Pacific Dengue vaccine programme from Thailand and the Philippines.
Clinical trials have been completed in a mix of non-endemic and endemic countries, namely the United States of America, Mexico and the Philippines. However, clinical studies of Asian adults and child subjects are ongoing in the Philippines and Thailand as well as in Peru and Mexico in Latin America. With specific reference to Thailand’s children, the goal of the studies is to determine vaccine efficacy against asymptomatic Dengue.
The initial results show that three doses of the vaccine are sufficient to elicit a balanced immunological response against the four Dengue serotypes. Additionally, tolerance and safety appear to be good.
Sanofi Pasteur is working jointly with Singapore’s Communicable Disease Centre and Vietnam’s Pasteur Institute. Sanofi Pasteur is the vaccines arm of sanofi-aventis Group. Their tetravalent Dengue vaccine, the first to get this far along, targets all four Dengue virus strains simultaneously.
5
THING YOU DID NOT KNOW ABOUT MOSQUITOES.... It would take 1,200,000 mosquitoes, each sucking once, to completely drain the average human of blood. (Sources: discovermagazine.com / anannimos.blogspot.com) - Now you know.
Woodshed Environment Coalition 